BG-12 (Dimethyl Fumarate) Treatment for Relapsing–Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies (P07.106)
暂无分享,去创建一个
L. Kappos | R. Gold | E. Havrdová | G. Giovannoni | S. Sheikh | K. Dawson | R. Fox | A. Zhang | V. Viglietta | J. Phillips | N. Kurukulasuriya